Comparative Pharmacology
Head-to-head clinical analysis: ESTRADIOL CYPIONATE versus LYGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRADIOL CYPIONATE versus LYGEN.
ESTRADIOL CYPIONATE vs LYGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol cypionate is a synthetic ester of estradiol, a form of estrogen. It binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and leading to effects such as development of female secondary sexual characteristics, regulation of menstrual cycle, and maintenance of reproductive tissues. It also has effects on bone density, lipid metabolism, and coagulation factors.
Lysergic acid diethylamide (LSD) acts as a partial agonist at serotonin 5-HT2A receptors in the brain, leading to altered glutamatergic signaling and neural network modulation.
1-5 mg intramuscularly every 3-4 weeks.
For adults, administer 500 mg orally twice daily with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 7–9 days following intramuscular injection, reflecting prolonged absorption from the oil depot.
12 hours; prolonged to 24 hours in severe renal impairment (CrCl <30 mL/min)
Primarily renal (approximately 90% as glucuronide and sulfate conjugates; less than 5% as unchanged drug). Biliary/fecal elimination accounts for about 10%.
Renal (90% as unchanged drug), biliary/fecal (10%)
Category D/X
Category C
Estrogen
Estrogen